A recent article from Fierce Biotech highlights the world's top emerging biotech hubs for 2026, showcasing the regions attracting investment, innovation and the next generation of life sciences companies. As these biotech ecosystems continue to grow, proximity matters. With offices strategically located in London, Berlin, Philadelphia and Shanghai, Clinical Services International (CSI) is well positioned to support sponsors across many of these fast-growing life sciences hubs

As we prepare for Q1 2026, sponsors and CROs face a shifting global landscape for clinical trial comparator sourcing that focuses on sustainability, diversity and fair pricing. With our EcoVadis Platinum certification, women-owned business status and full scientific team in place, CSI is well placed to support our partner’s supply chains. 1. Supply-chain volatility is real Clinical supplies are increasingly challenged by geo-political pressures, export controls, and manufactu

Strategy Partnerships for Budget Value As we enter Q4, many clinical operations teams face the familiar challenge of budget utilization. In research-driven organizations, unspent funds create pressure to allocate resources quickly. Yet, reactive decisions can compromise study timelines, inflate costs, or affect compliance. The question becomes: how can sponsors and CROs transform year-end budget pressures into a strategic advantage? From Short-Term Spending to Strategic Inves

Request A global listed Biotech company required large quantities of Eylea Pre-Filled Syringes (PFS) sourced across both the EU and USA. Their priorities included: Relatively Stable pricing over a 2-3 year period Best possible expiry dates to accommodate packaging timelines (losing 6-8 weeks in the process) Ensuring continuous supply by replenishing stock before expiry (~14-16 months) Bulk procurement in single large batches for efficiency in regular intervals Challenges Ma